BerberineNew

Reviewed Sep 6, 2026

Berberine is a plant alkaloid that activates the cellular energy sensor AMPK and partially inhibits mitochondrial Complex I — mechanisms it shares with metformin — while also reshaping the gut microbiome. The 2024-2026 evidence base is now sizeable. A 2025 systematic review and meta-analysis of randomized placebo-controlled trials in people with metabolic syndrome (Frontiers in Pharmacology) found that berberine significantly reduced fasting plasma glucose (weighted mean difference -0.52 mmol/L), 2-hour post-load glucose (-1.61 mmol/L), triglycerides (-0.37 mmol/L), LDL cholesterol (-0.50 mmol/L), total cholesterol (-0.45 mmol/L), waist circumference (-3.27 cm) and BMI (-0.44 kg/m²), with no significant change in HDL or blood pressure and a safety profile comparable to placebo. An earlier umbrella meta-analysis of pooled randomized trials (Clinical Therapeutics, 2023) similarly reported meaningful reductions in HbA1c, HOMA-IR insulin resistance and the inflammatory markers CRP, IL-6 and TNF-α. More recent work extends these effects to the liver: a 2025 clinical-and-preclinical meta-analysis (Frontiers in Pharmacology) found berberine lowered fasting glucose in people with non-alcoholic fatty liver disease, and a 2026 network meta-analysis of herbal agents in metabolic dysfunction-associated steatotic liver disease (Gastro Hep Advances) ranked berberine among the more effective options for lowering the liver enzymes AST and GGT. The main limitations are modest trial sizes, heterogeneity between studies, and berberine's low oral bioavailability, which is why it is dosed in divided amounts with meals. Berberine is a dietary supplement, not a drug, and is not intended to diagnose, treat, cure or prevent any disease; it can interact with many medications (it inhibits CYP3A4/CYP2D6) and may cause hypoglycemia when combined with glucose-lowering drugs. Discuss use with your physician before starting.